PH26827A - A locally administrable therapeutic composition for inflammatory disease - Google Patents

A locally administrable therapeutic composition for inflammatory disease Download PDF

Info

Publication number: PH26827A
Authority: PH; Philippines
Prior art keywords: eye; inflammatory; acid; sodium; salt
Prior art date: 1988-01-27

Application number

PH38108A

Other languages

English (en)

Inventor

Takahiro Ogawa

Yoshikazu Kuribayashi

Original Assignee

Senju Pharma Co

Robins Co Inc A H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-27

Filing date

1989-01-26

Publication date

1992-11-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11923115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26827(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-01-26 Application filed by Senju Pharma Co, Robins Co Inc A H filed Critical Senju Pharma Co

1991-05-20 Priority to PH42478A priority Critical patent/PH30230A/en

1992-11-05 Publication of PH26827A publication Critical patent/PH26827A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 41
230000001225 therapeutic effect Effects 0.000 title claims abstract description 7
208000027866 inflammatory disease Diseases 0.000 title claims abstract description 5
230000002757 inflammatory effect Effects 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 18
239000002253 acid Substances 0.000 claims abstract description 12
239000004480 active ingredient Substances 0.000 claims abstract description 10
125000005843 halogen group Chemical group 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 53
239000003795 chemical substances by application Substances 0.000 claims description 14
230000003110 anti-inflammatory effect Effects 0.000 claims description 13
206010061218 Inflammation Diseases 0.000 claims description 10
230000004054 inflammatory process Effects 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 9
238000000034 method Methods 0.000 claims description 7
239000003885 eye ointment Substances 0.000 claims description 5
YVKSMFUEDUPYIF-UHFFFAOYSA-N 3-oxo-2,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(=O)C1=CC=CC=C1 YVKSMFUEDUPYIF-UHFFFAOYSA-N 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
230000002335 preservative effect Effects 0.000 claims description 3
210000000613 ear canal Anatomy 0.000 claims 2
230000000813 microbial effect Effects 0.000 claims 1
125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
229940069265 ophthalmic ointment Drugs 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 28
229940079593 drug Drugs 0.000 abstract description 28
230000000694 effects Effects 0.000 abstract description 13
230000000699 topical effect Effects 0.000 abstract description 7
208000030533 eye disease Diseases 0.000 abstract description 3
IVDWXSTVNDRJDG-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-oxo-3-phenylpropanoic acid Chemical compound C1=CC(OCC)=CC=C1C(C(O)=O)C(=O)C1=CC=CC=C1 IVDWXSTVNDRJDG-UHFFFAOYSA-N 0.000 abstract 1
208000026344 Nasal disease Diseases 0.000 abstract 1
208000030880 Nose disease Diseases 0.000 abstract 1
239000002085 irritant Substances 0.000 abstract 1
231100000021 irritant Toxicity 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
239000011780 sodium chloride Substances 0.000 description 17
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
239000011734 sodium Substances 0.000 description 14
229910052708 sodium Inorganic materials 0.000 description 14
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
229910021538 borax Inorganic materials 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
235000010339 sodium tetraborate Nutrition 0.000 description 10
239000000243 solution Substances 0.000 description 10
241001420836 Ophthalmitis Species 0.000 description 9
229960000686 benzalkonium chloride Drugs 0.000 description 9
208000010403 panophthalmitis Diseases 0.000 description 9
239000002504 physiological saline solution Substances 0.000 description 9
239000004328 sodium tetraborate Substances 0.000 description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
239000001267 polyvinylpyrrolidone Substances 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
239000002997 ophthalmic solution Substances 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
206010030113 Oedema Diseases 0.000 description 6
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
229940054534 ophthalmic solution Drugs 0.000 description 6
235000010265 sodium sulphite Nutrition 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 5
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 5
239000004327 boric acid Substances 0.000 description 5
239000003889 eye drop Substances 0.000 description 5
150000003431 steroids Chemical class 0.000 description 5
-1 alkaline earth metal salts Chemical class 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
229960000396 atropine Drugs 0.000 description 4
235000010418 carrageenan Nutrition 0.000 description 4
229920001525 carrageenan Polymers 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
229950008882 polysorbate Drugs 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
229940037001 sodium edetate Drugs 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
229930003347 Atropine Natural products 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000002159 anterior chamber Anatomy 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940012356 eye drops Drugs 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
150000004682 monohydrates Chemical class 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
UQFHJDVUQSAVOQ-UHFFFAOYSA-N (2-aminophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1N UQFHJDVUQSAVOQ-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
206010027646 Miosis Diseases 0.000 description 2
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
101710089165 Protein white Proteins 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004820 blood count Methods 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
239000006196 drop Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
230000000622 irritating effect Effects 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
230000003547 miosis Effects 0.000 description 2
229940100656 nasal solution Drugs 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
229940100685 otic solution Drugs 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
BIYQNLJPABKADF-UHFFFAOYSA-M sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 BIYQNLJPABKADF-UHFFFAOYSA-M 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012353 t test Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical class C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
HOKIDJSKDBPKTQ-UHFFFAOYSA-N 3-(acetyloxymethyl)-7-[(5-amino-5-carboxypentanoyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C(NC(=O)CCCC(N)C(O)=O)C12 HOKIDJSKDBPKTQ-UHFFFAOYSA-N 0.000 description 1
125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000269350 Anura Species 0.000 description 1
241001167018 Aroa Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010011039 Corneal perforation Diseases 0.000 description 1
241000581877 Fiona Species 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
238000006165 Knowles reaction Methods 0.000 description 1
241000763212 Lype Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
244000184734 Pyrus japonica Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010520 ghee Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
235000019252 potassium sulphite Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000003259 prostaglandin group Chemical group 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
FVBKCOXGVZPEDP-UHFFFAOYSA-M sodium;2-[2-amino-3-(4-chlorobenzoyl)phenyl]acetate Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Cl)C=C1 FVBKCOXGVZPEDP-UHFFFAOYSA-M 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PH38108A 1988-01-27 1989-01-26 A locally administrable therapeutic composition for inflammatory disease PH26827A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
PH42478A PH30230A (en)	1988-01-27	1991-05-20	A locally administrable therapeutic composition for inflammatory disease

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP1668388		1988-01-27

Publications (1)

Publication Number	Publication Date
PH26827A true PH26827A (en)	1992-11-05

Family

ID=11923115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38108A PH26827A (en)	1988-01-27	1989-01-26	A locally administrable therapeutic composition for inflammatory disease

Country Status (12)

Country	Link
US (1)	US4910225A (de)
EP (1)	EP0326915B1 (de)
JP (1)	JP2683676B2 (de)
KR (1)	KR960005707B1 (de)
AT (1)	ATE80043T1 (de)
AU (1)	AU609932B2 (de)
CA (1)	CA1325382C (de)
DE (1)	DE68902649T2 (de)
ES (1)	ES2052784T3 (de)
GR (1)	GR3005586T3 (de)
HK (1)	HK162895A (de)
PH (1)	PH26827A (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5897858A (en)	1994-02-03	1999-04-27	Schering-Plough Healthcare Products, Inc.	Nasal spray compositions exhibiting increased retention in the nasal cavity
US5475034A (en) *	1994-06-06	1995-12-12	Alcon Laboratories, Inc.	Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5895645A (en) *	1995-01-31	1999-04-20	Bausch & Lomb Incorporated	Opthalmic solution for artificial tears
RU2116070C1 (ru) *	1996-07-08	1998-07-27	Севиньдж Исмаил кызы Акберова	Фармацевтическая композиция
AR020661A1 (es) *	1998-09-30	2002-05-22	Alcon Lab Inc	Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
DE19961307A1 (de) *	1999-12-18	2001-07-12	Krewel Meuselbach Gmbh	Medizinprodukt zur Befeuchtung und Reinigung der Nasenschleimhaut
AR030346A1 (es)	2000-08-14	2003-08-20	Alcon Inc	Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) *	2000-08-14	2003-08-20	Alcon Inc	Metodo de tratamiento de desordenes relacionados con angiogenesis
AU2002247284A1 (en)	2001-04-02	2002-10-15	Alcon, Inc.	Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
US7030149B2 (en)	2002-04-19	2006-04-18	Allergan, Inc.	Combination of brimonidine timolol for topical ophthalmic use
US20030207941A1 (en) *	2002-05-03	2003-11-06	Bingaman David P.	Method of treating vascular endothelial growth factor mediated vascular disorders
EP1586316B1 (de) *	2003-01-21	2008-04-30	Senju Pharmaceutical Co., Ltd.	Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure
US20030187072A1 (en) *	2003-02-14	2003-10-02	Kapin Michael A.	Method of treating angiogenesis-related disorders
CA2527121A1 (en) *	2003-06-13	2004-12-29	Alcon, Inc.	Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
ATE552838T1 (de) *	2003-11-14	2012-04-15	Senju Pharma Co	Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac
FR2876581B1 (fr) *	2004-10-20	2007-05-18	Interpharm Dev	Composition bioadhesive a liberation programmee
CN1993118B (zh)	2004-11-05	2010-06-16	千寿制药株式会社	促进眼内渗透性的水性滴眼剂
TWI358290B (en) *	2004-12-02	2012-02-21	Alcon Inc	Topical nepafenac formulations
PT1906916E (pt) *	2005-05-10	2008-12-10	Alcon Inc	Suspensão oftálmica compreendendo um fármaco oftálmico, uma poloxamina e um agente de ajuste da tonicidade de glicol, utilização da referida composição para a produção de um medicamento para o tratamento de distúrbios oftálmicos
DK1885336T3 (da) *	2005-05-10	2009-05-25	Alcon Inc	Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
US20070254841A1 (en) *	2006-01-25	2007-11-01	Ophthalmic Research Associates, Inc.	Formulations and methods for treating dry eye
US20100130580A1 (en) *	2006-01-25	2010-05-27	Aciex Therapeutics, Inc.	Formulations and Methods for Treating Dry Eye
TW200812575A (en) *	2006-04-28	2008-03-16	Alcon Inc	Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20090105245A1 (en) *	2006-12-21	2009-04-23	Bingaman David P	Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
US20080153818A1 (en) *	2006-12-21	2008-06-26	Bingaman David P	Methods for preventing inflammation during surgery
US20080153819A1 (en) *	2006-12-21	2008-06-26	Bingaman David P	Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
UY31058A1 (es) *	2007-05-01	2008-10-31	Alcon Res Ltd	Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
MX2009012645A (es) *	2007-05-24	2010-03-08	Aciex Therapeutics Inc	Formulaciones y metodos para tratar el ojo seco.
BRPI0908502A2 (pt) *	2008-02-21	2017-05-23	Ista Pharmaceuticals	aines oftálmicos como adjuvantes
US8778999B2 (en) *	2009-03-05	2014-07-15	Insite Vision Incorporated	Non-steroidal anti-inflammatory ophthalmic compositions
US8299295B2 (en)	2009-10-15	2012-10-30	Johnson Matthey Public Limited Company	Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB0919757D0 (en)	2009-11-12	2009-12-30	Johnson Matthey Plc	Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US9522153B2 (en)	2009-12-22	2016-12-20	Allergan, Inc.	Compositions and methods for lowering intraocular pressure
WO2012099142A1 (ja)	2011-01-18	2012-07-26	千寿製薬株式会社	保存効力を有するブロムフェナク水性液剤組成物
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko)	2012-05-03	2020-08-04	칼라 파마슈티컬스, 인크.	개선된 점막 수송을 나타내는 제약 나노입자
ES3055223T3 (en)	2012-05-03	2026-02-10	Alcon Inc	Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
JP6128572B2 (ja)	2012-11-19	2017-05-17	ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ＆ＬｏｍｂＩｎｃｏｒｐｏｒａｔｅｄ	２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸を含有する水性液体組成物
HK1217092A1 (zh)	2013-02-15	2016-12-23	Kala Pharmaceuticals, Inc.	治疗性化合物及其用途
BR112015020139A2 (pt)	2013-02-20	2017-07-18	Kala Pharmaceuticals Inc	compostos terapêuticos e usos dos mesmos
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20160143869A1 (en)	2013-06-19	2016-05-26	Sentiss Research Center	Stable bromfenac solution
KR20160099084A (ko)	2013-11-01	2016-08-19	칼라 파마슈티컬스, 인크.	치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2015087267A2 (en)	2013-12-12	2015-06-18	Sentiss Pharma Private Limited	Stable bromfenac ophthalmic solution
CN106404952B (zh) *	2016-08-31	2019-06-11	辰欣佛都药业（汶上）有限公司	一种溴芬酸钠滴眼液有关物质的测定方法
EP3509423A4 (de)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	Kristalline formen von therapeutischen verbindungen und verwendungen davon
CA3036336A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
JPWO2019117252A1 (ja) *	2017-12-14	2020-12-17	参天製薬株式会社	２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸またはその塩を含有する点眼剤
WO2022092868A1 (ko)	2020-10-29	2022-05-05	주식회사태준제약	안과용 조성물
KR102489633B1 (ko)	2021-01-21	2023-01-17	주식회사태준제약	점안 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU512570B2 (en) *	1975-08-13	1980-10-16	A.H. Robins Company, Incorporated	Amino benzophenones
CH577461A5 (de) *	1975-08-13	1976-07-15	Robins Co Inc A H
JPS58201710A (ja) *	1982-05-18	1983-11-24	Meiji Seika Kaisha Ltd	口腔内用抗炎症ペ−スト剤
US4568695A (en) *	1983-12-07	1986-02-04	A. H. Robins Company, Incorporated	2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) *	1985-10-28	1987-07-28	A. H. Robins Company, Incorporated	Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters

1989
- 1989-01-24 CA CA000589025A patent/CA1325382C/en not_active Expired - Lifetime
- 1989-01-24 US US07/301,033 patent/US4910225A/en not_active Expired - Lifetime
- 1989-01-25 DE DE8989101237T patent/DE68902649T2/de not_active Expired - Lifetime
- 1989-01-25 ES ES89101237T patent/ES2052784T3/es not_active Expired - Lifetime
- 1989-01-25 AT AT89101237T patent/ATE80043T1/de not_active IP Right Cessation
- 1989-01-25 AU AU28786/89A patent/AU609932B2/en not_active Expired
- 1989-01-25 EP EP89101237A patent/EP0326915B1/de not_active Expired - Lifetime
- 1989-01-26 PH PH38108A patent/PH26827A/en unknown
- 1989-01-27 KR KR1019890000892A patent/KR960005707B1/ko not_active Expired - Lifetime
- 1989-01-27 JP JP1018549A patent/JP2683676B2/ja not_active Expired - Lifetime
1992
- 1992-09-03 GR GR920401848T patent/GR3005586T3/el unknown
1995
- 1995-10-19 HK HK162895A patent/HK162895A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE68902649T2 (de)	1993-02-11
US4910225A (en)	1990-03-20
AU609932B2 (en)	1991-05-09
CA1325382C (en)	1993-12-21
DE68902649D1 (de)	1992-10-08
HK162895A (en)	1995-10-27
JP2683676B2 (ja)	1997-12-03
ATE80043T1 (de)	1992-09-15
KR960005707B1 (ko)	1996-05-01
JPH02124817A (ja)	1990-05-14
EP0326915A1 (de)	1989-08-09
KR890011823A (ko)	1989-08-22
AU2878689A (en)	1989-07-27
ES2052784T3 (es)	1994-07-16
GR3005586T3 (de)	1993-06-07
EP0326915B1 (de)	1992-09-02

Publication	Publication Date	Title
PH26827A (en)	1992-11-05	A locally administrable therapeutic composition for inflammatory disease
US5110493A (en)	1992-05-05	Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
NL192821C (nl)	1998-03-04	Oftalmische oplossing.
HU211972A9 (en)	1996-01-29	Antiallergic composition for ophthalmic or nasal use
HK27894A (en)	1994-03-31	Preservative system for ophtalmic formulations
CN107405360B (zh)	2019-08-27	新颖碘伏组合物及其使用方法
JPS6038323A (ja)	1985-02-27	眼科用消炎剤
JPH0696521B2 (ja)	1994-11-30	眼局所投与用眼圧降下剤
CN101175487B (zh)	2011-11-16	依布硒啉的制药用途
US10973758B2 (en)	2021-04-13	Methods of eye treatment using therapeutic compositions containing dipyridamole
JP6320616B1 (ja)	2018-05-09	新規眼科用組成物および使用方法
WO2019135779A1 (en)	2019-07-11	Novel ophthalmic composition and methods of use
JPS5929616A (ja)	1984-02-16	抗炎症眼科用液剤およびその製法
EP0728480A1 (de)	1996-08-28	Verwendung von Ifenprodil zur Behandlung von erhöhtem Augeninnendruck
US5428030A (en)	1995-06-27	Method of reducing elevated intraocular pressure
RU2657419C1 (ru)	2018-06-13	Фармацевтическая композиция для назального применения
KR950013745B1 (ko)	1995-11-15	안과 제제용 방부 시스템
JPH10203979A (ja)	1998-08-04	チアプロフェン酸を含有する抗眼炎症剤
JPH0778022B2 (ja)	1995-08-23	緑内障治療剤
JPS63201122A (ja)	1988-08-19	トリフルオロメタンスルホンアミドを含有する緑内障治療配合物
US20180200289A1 (en)	2018-07-19	Novel ophthalmic composition and methods of use
JP2002322060A (ja)	2002-11-08	粘膜適用組成物
JPS63179825A (ja)	1988-07-23	局所抗炎症剤
JPH0797318A (ja)	1995-04-11	オキシフェドリンを必須成分とする眼圧降下剤
JPH09295935A (ja)	1997-11-18	抗眼炎症剤